In this study they demonstrated that the perinecrotic regions of GBM display an upregulation of transglutaminase 2 (TGM2) expression, providing evidence that TGM2 is involved in the transition towards a MES phenotype; indeed, they demonstrated that, upon TGM2 silencing in MES GSCs, both MES MRs and MES markers were downregulated, while the contrary occurred in PN GSCs by TGM2 overexpression. The gene discussed is TGM2; the disease is glioblastoma.